应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BIOA BioAge Labs Inc.
未开盘 07-17 16:00:00 EDT
4.80
+0.17
+3.67%
盘后
4.75
-0.05
-1.04%
19:26 EDT
最高
4.82
最低
4.59
成交量
12.29万
今开
4.62
昨收
4.63
日振幅
5.08%
总市值
1.72亿
流通市值
1.14亿
总股本
3,585万
成交额
58.43万
换手率
0.52%
流通股本
2,382万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Bioage Labs, Inc.2025财年第一财季实现净利润-12.93百万美元,同比增加0.46%
市场透视 · 05-12
Bioage Labs, Inc.2025财年第一财季实现净利润-12.93百万美元,同比增加0.46%
异动解读 | 生物科技新星BioAge Labs纳斯达克上市首日大涨6.36%
异动解读 · 2024-09-27
异动解读 | 生物科技新星BioAge Labs纳斯达克上市首日大涨6.36%
异动解读 | 生物科技新星BioAge Labs纳斯达克挂牌上市 股价大涨5.73%
异动解读 · 2024-09-27
异动解读 | 生物科技新星BioAge Labs纳斯达克挂牌上市 股价大涨5.73%
生物科技公司BioAge Labs纳斯达克上市:市值6亿美元 路演PPT曝光
雷递网 · 2024-09-27
生物科技公司BioAge Labs纳斯达克上市:市值6亿美元 路演PPT曝光
异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景
异动解读 · 2024-09-26
异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景
减肥药研发公司BioAge Labs(BIOA.US)扩大发行规模至1100万股 IPO定价18美元
智通财经网 · 2024-09-26
减肥药研发公司BioAge Labs(BIOA.US)扩大发行规模至1100万股 IPO定价18美元
生物科技初创公司BioAge Labs(BIOA.US)IPO定价17-19美元/股 拟筹资1.35亿美元
智通财经 · 2024-09-19
生物科技初创公司BioAge Labs(BIOA.US)IPO定价17-19美元/股 拟筹资1.35亿美元
加载更多
公司概况
公司名称:
BioAge Labs Inc.
所属市场:
NASDAQ
上市日期:
2024-09-26
主营业务:
BioAge Labs, Inc.于2015年4月1日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,通过针对人类衰老的生物学特性,开发治疗肥胖等代谢性疾病的候选产品。他们的技术平台和差异化的人类数据集使他们能够根据对驱动衰老的分子变化的见解来识别有前景的靶点。他们的主要关注点是代谢性疾病,这是全球最大的医疗保健挑战之一。
发行价格:
18.00
{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":4.8,"timestamp":1752782400000,"preClose":4.63,"halted":0,"volume":122906,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.8,"latestTime":"19:26 EDT","volume":1884,"amount":9005.4,"timestamp":1752794802889},"delay":0,"floatShares":23819976,"shares":35850037,"eps":-3.686692,"marketStatus":"未开盘","change":0.17,"latestTime":"07-17 16:00:00 EDT","open":4.62,"high":4.82,"low":4.585,"amount":584322.040414,"amplitude":0.050756,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.686692,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752825600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":4.63,"preHourTrading":{"tag":"盘前","latestPrice":4.63,"preClose":4.63,"latestTime":"08:10 EDT","volume":4,"amount":18.52,"timestamp":1752754250680},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.8,"latestTime":"19:26 EDT","volume":1884,"amount":9005.4,"timestamp":1752794802889},"volumeRatio":0.902624,"impliedVol":2.4642,"impliedVolPercentile":0.8692},"requestUrl":"/m/hq/s/BIOA","defaultTab":"news","newsList":[{"id":"2535044242","title":"Bioage Labs, Inc.2025财年第一财季实现净利润-12.93百万美元,同比增加0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535044242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535044242?lang=zh_cn&edition=full","pubTime":"2025-05-13 00:00","pubTimestamp":1747065639,"startTime":"0","endTime":"0","summary":"5月13日,Bioage Labs, Inc.公布财报,公告显示公司2025财年第一财季净利润为-12.93百万美元,同比增加0.46%;其中营业收入为1.45百万美元,每股基本收益为-0.36美元。从资产负债表来看,Bioage Labs, Inc.总负债30.67百万美元,其中短期债务6.70百万美元,资产负债比为0.12,流动比率为0.14。机构评级:截至2025年5月13日,当前有3家机构对Bioage Labs, Inc.目标价做出预测,其中目标均价为4.67美元,其中最低目标价为4.00美元,最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513000058a6dc725e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513000058a6dc725e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIOA"],"gpt_icon":0},{"id":"1186878787","title":"异动解读 | 生物科技新星BioAge Labs纳斯达克上市首日大涨6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186878787","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186878787?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:36","pubTimestamp":1727444184,"startTime":"0","endTime":"0","summary":"9月27日,生物科技新星BioAge Labs Inc.在美国纳斯达克交易所成功挂牌上市,股价大涨6.36%,收于38.74美元,引发市场广泛关注。BioAge Labs主攻代谢疾病等人类衰老相关疾病的治疗领域,其主要候选药物azelaprag在多项临床试验中表现出良好的安全性和有效性。此外,生物科技公司是今年美国IPO市场的一大亮点,活跃的IPO市场为BioAge Labs上市大涨提供了良好环境。投资者偏好盈利前景明朗的公司,生物科技龙头BioAge Labs自然成为资金追捧对象。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"gpt_icon":0},{"id":"1163589295","title":"异动解读 | 生物科技新星BioAge Labs纳斯达克挂牌上市 股价大涨5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163589295","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163589295?lang=zh_cn&edition=full","pubTime":"2024-09-27 20:56","pubTimestamp":1727441784,"startTime":"0","endTime":"0","summary":"生物科技新星BioAge Labs Inc.于2024年9月26日在美国纳斯达克交易所成功挂牌上市,首日股价大涨5.73%,反映了投资者对该公司未来发展前景的乐观预期。BioAge Labs主攻代谢疾病等人类衰老相关疾病的治疗领域,其主要候选药物azelaprag是一种口服小分子,已在多项临床试验中表现出良好的安全性和有效性。据招股书披露,BioAge Labs虽然暂无营收,但已累计获得超过3亿美元融资,投资者包括知名风险投资机构Andreessen Horowitz、Khosla Ventures等。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"gpt_icon":0},{"id":"2470971613","title":"生物科技公司BioAge Labs纳斯达克上市:市值6亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2470971613","media":"雷递网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470971613?lang=zh_cn&edition=full","pubTime":"2024-09-27 09:01","pubTimestamp":1727398919,"startTime":"0","endTime":"0","summary":"生物科技初创公司BioAge Labs(股票代码为:“BIOA”)昨日在美国纳斯达克上市,募资总额为1.98亿美元。BioAge Labs开盘价为22.5美元,较发行价上涨25%;收盘价为18.31美元,较发行价上涨1.72%;以收盘价计算,公司市值为6.16亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240927/6386302451252659998745633.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240927/6386302451252659998745633.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n27839/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4007","QLD","BK1147","ARTL","SQQQ","NQmain","03086",".IXIC","QID","PSQ","PPT","TQQQ","MNQmain","BIOA"],"gpt_icon":1},{"id":"1174058188","title":"异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1174058188","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174058188?lang=zh_cn&edition=full","pubTime":"2024-09-27 00:16","pubTimestamp":1727367379,"startTime":"0","endTime":"0","summary":"在纳斯达克交易的生物科技公司BioAge Labs Inc. 股价今日大涨25%,引发了市场的广泛关注。从公司最新消息来看,这与其正在积极筹备的首次公开募股有直接关联。据悉,BioAge Labs计划以每股18美元的价格发行1100万股新股,募集资金高达1.98亿美元。BioAge Labs的主打产品Azelaprag是一种口服小分子药物,已在8个1期临床试验中展现出良好的安全性和耐受性。公司目前正在开展Azelaprag与现有减肥药联合用药的2期临床试验,有望成为全口服肥胖症联合疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"gpt_icon":0},{"id":"2470813206","title":"减肥药研发公司BioAge Labs(BIOA.US)扩大发行规模至1100万股 IPO定价18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470813206","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470813206?lang=zh_cn&edition=full","pubTime":"2024-09-26 15:59","pubTimestamp":1727337555,"startTime":"0","endTime":"0","summary":"生物科技初创公司BioAge Labs正在筹划通过首次公开发行(IPO)筹集高达1.98亿美元的资金。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240926/20240926155504_53537.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240926/20240926155504_53537.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BIOA"],"gpt_icon":0},{"id":"2468083543","title":"生物科技初创公司BioAge Labs(BIOA.US)IPO定价17-19美元/股 拟筹资1.35亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468083543","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468083543?lang=zh_cn&edition=full","pubTime":"2024-09-19 14:50","pubTimestamp":1726728600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,生物科技初创公司BioAge Labs于周三公布了其 IPO 条款,该公司计划以 17 至 19 美元的价格区间发行 750 万股股票,筹集 1.35 亿美元。按照提议的范围的中间值,BioAge Labs 的市值将达到 6.02 亿美元。BioAge Labs的主要关注点是代谢疾病,这是全球最大的医疗保健挑战之一。BioAge Labs的主要候选产品 Azelaprag是一种口服小分子,在8个 1 期临床试验中,265 名受试者的耐受性良好。BioAge Labs在2022年、2023年运营亏损分别为3997万美元、4840万美元;净亏损分别为3972万美元、6385万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIOA","159837"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":0.1034},{"period":"3month","weight":0.2403},{"period":"6month","weight":-0.0661},{"period":"1year","weight":-0.7333},{"period":"ytd","weight":-0.171}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1931},{"period":"6month","weight":0.051},{"period":"1year","weight":0.1277},{"period":"ytd","weight":0.0716}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioAge Labs, Inc.于2015年4月1日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,通过针对人类衰老的生物学特性,开发治疗肥胖等代谢性疾病的候选产品。他们的技术平台和差异化的人类数据集使他们能够根据对驱动衰老的分子变化的见解来识别有前景的靶点。他们的主要关注点是代谢性疾病,这是全球最大的医疗保健挑战之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioAge Labs Inc.(BIOA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioAge Labs Inc.(BIOA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}